胃癌肝转移三线采用甲磺酸阿帕替尼联合伊立替康治疗1例

A case of apatinib mesylate combined with irinotecan in the third-line treatment of liver metastases from gastric cancer

胃癌远处转移后预后较差,生存期明显缩短。现报道1例胃癌多发肝转移,癌胚抗原(CEA)高达275.0ng/mL晚期患者的诊疗过程,三线采用甲磺酸阿帕替尼联合伊立替康治疗后无进展生存期(PFS)长达7月余,为晚期胃癌提供可选择的新方案。